Novo CSO: This is how much we will spend on R&D
Novo Nordisk is currently conducting large-scale studies with new insulin drug Tresiba, as well as ground-breaking research within oral diabetes treatments. CSO Mads Krogsgaard Thomsen sheds light on the Danish pharma group’s expectations for the coming year.
by Stefan Singh Kailay
In 2012, Novo Nordisk conducted clinical research totalling about 15,000 patient-years, and that number is expected to be the same this year, while expectations for 2014 are even bigger, as the company expects clinical research of app. 25,000 patient-years.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo-CSO: It is all on a very speculative level
For abonnenter
Novo-CSO: It’s a setback, we have to admit it
For abonnenter
